This company has been marked as potentially delisted and may not be actively trading. NYSE:AGN Allergan (AGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Allergan Stock (NYSE:AGN) Get Allergan alerts:Sign Up Key Stats Today's Range$191.64▼$193.3850-Day Range$184.04▼$193.8952-Week Range$114.27▼$202.21Volume12.44 million shsAverage Volume4.01 million shsMarket Capitalization$63.50 billionP/E RatioN/ADividend Yield1.53%Price TargetN/AConsensus RatingN/A Company Overview Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland. Read More Receive AGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergan and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGN Stock News HeadlinesIncyte Shares Gain Following Appointment of New CEO Bill MeuryJune 26, 2025 | msn.comA Montreal woman is the lead plaintiff in Allergan breast implant class actionMay 24, 2025 | msn.comOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.October 19 at 2:00 AM | Banyan Hill Publishing (Ad)Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV)May 3, 2025 | gurufocus.comAlgernon Pharmaceuticals Inc.: Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney DiseaseApril 8, 2025 | finanznachrichten.deAllergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025March 24, 2025 | prnewswire.comAllergan Aesthetics to Launch Immersive Training Centers Worldwide in Advanced Aesthetics Techniques for Health Care ProfessionalsMarch 7, 2025 | msn.comEarnings call transcript: AbbVie Q4 2024 beats expectations, shares riseFebruary 1, 2025 | msn.comSee More Headlines AGN Stock Analysis - Frequently Asked Questions How were Allergan's earnings last quarter? Allergan plc (NYSE:AGN) issued its quarterly earnings data on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, topping the consensus estimate of $4.57 by $0.65. The firm's revenue for the quarter was up 6.6% on a year-over-year basis. What other stocks do shareholders of Allergan own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allergan investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU) and Aegean Marine Petroleum Network (ANW). Company Calendar Last Earnings2/10/2020Today10/19/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNYSE:AGN Previous SymbolNYSE:ACT CIK1578845 Webwww.allergan.com Phone862-261-7000FaxN/AEmployees17,400Year FoundedN/AProfitability EPS (Trailing Twelve Months)$17.64 Trailing P/E RatioN/A Forward P/E Ratio11.56 P/E Growth1.63Net Income-$5.27 billion Net Margins-15.44% Pretax MarginN/A Return on Equity8.46% Return on Assets5.31% Debt Debt-to-Equity Ratio0.31 Current Ratio1.01 Quick Ratio0.84 Sales & Book Value Annual Sales$16.09 billion Price / Sales3.95 Cash Flow$36.70 per share Price / Cash Flow5.26 Book Value$177.28 per share Price / Book1.09Miscellaneous Outstanding Shares329,002,000Free FloatN/AMarket Cap$63.50 billion OptionableOptionable Beta1.20 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NYSE:AGN) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergan plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergan With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.